New T cell therapies for childhood cancers
NGTC - INSERM
This study is working on new T cell treatments for kids with solid tumors, like certain types of sarcomas and brain cancers, to help them fight their cancer more effectively and safely, with the hope of making these treatments available in the next ten years.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inserm Paris 5 NIH-funded |
| Lab location | 1 site (Paris, France) |
| Project ID | NIH-10647981 on NIH RePORTER |
What this research studies
This research focuses on developing advanced T cell therapies specifically designed for treating childhood solid cancers, which are often resistant to current treatments. By utilizing engineered T cells, the research aims to create therapies that can provide durable responses without long-term toxicity. The approach involves detailed studies of primary tumors to identify new targets and understand the tumor microenvironment, which can hinder T cell function. The project is structured into interconnected work packages, initially targeting pediatric sarcomas and brain tumors, with the goal of making these therapies routine within a decade.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with solid tumors, particularly pediatric sarcomas and brain tumors.
Not a fit: Patients with hematologic malignancies or those whose tumors do not respond to T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective and safe treatments for children suffering from solid tumors, significantly improving their chances of recovery.
How similar studies have performed: Other research has shown promising results with engineered T cell therapies in adult cancers, suggesting potential for success in pediatric applications.
Where this research is happening
Paris, France
- Inserm Paris 5 — Paris, France (Active)
Researchers
- Principal investigator: Donnadieu, Emmanuel — Inserm Paris 5
- Study coordinator: Donnadieu, Emmanuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.